Literature DB >> 26757272

Prior hysterectomy and oophorectomy and incident venous thrombosis risk among postmenopausal women: a population-based, case-control study.

Laura B Harrington1, Noel S Weiss, Kerri L Wiggins, Susan R Heckbert, Barbara McKnight, Marc Blondon, Nancy F Woods, Andrea Z LaCroix, Bruce M Psaty, Nicholas L Smith.   

Abstract

OBJECTIVE: Hysterectomy and bilateral salpingo-oophorectomy (BSO) are associated with changes in endogenous hormone levels, yet the risk of venous thrombosis (VT) associated with hysterectomy and BSO is incompletely characterized. This study evaluated the risk of incident VT among postmenopausal women associated with combined prior hysterectomy/oophorectomy status and current use of hormone therapy (HT).
METHODS: In a case-control study, we identified incident VT cases (n = 1,623) among postmenopausal Group Health Cooperative enrollees without reproductive cancer, defining their "index date" as their VT diagnosis date (1995-2010). Matched controls had not experienced a prior VT (n = 4,480). Multiple logistic regression models estimated adjusted relative risks for VT associated with combinations of prior hysterectomy/oophorectomy status and HT use at the index date.
RESULTS: Compared with women with an intact uterus who were not using HT, there was no suggestion of greater VT risk in women with prior hysterectomy without BSO, whether they were (adjusted odds ratio [aOR] = 0.80 [95% CI: 0.57, 1.12]) or were not using HT (aOR = 1.09 [95% CI: 0.89, 1.35]). Women with prior hysterectomy and BSO who were using HT were not at a greater VT risk (OR = 1.00 [95% CI: 0.78, 1.27]), but there was evidence of a 25% greater risk associated with prior hysterectomy with BSO and no current HT use (OR = 1.25 [95% CI: 1.05, 1.49]).
CONCLUSIONS: Collectively, these and prior data do not suggest a substantial impact of hysterectomy, with or without BSO, on the risk of VT among postmenopausal women.

Entities:  

Mesh:

Year:  2016        PMID: 26757272      PMCID: PMC4731261          DOI: 10.1097/GME.0000000000000591

Source DB:  PubMed          Journal:  Menopause        ISSN: 1072-3714            Impact factor:   2.953


  25 in total

1.  Oophorectomy vs ovarian conservation with hysterectomy: cardiovascular disease, hip fracture, and cancer in the Women's Health Initiative Observational Study.

Authors:  Vanessa L Jacoby; Deborah Grady; Jean Wactawski-Wende; JoAnn E Manson; Matthew A Allison; Miriam Kuppermann; Gloria E Sarto; John Robbins; Lawrence Phillips; Lisa W Martin; Mary Jo O'Sullivan; Rebecca Jackson; Rebecca J Rodabough; Marcia L Stefanick
Journal:  Arch Intern Med       Date:  2011-04-25

Review 2.  Oral contraceptives and venous thromboembolism: a systematic review and meta-analysis.

Authors:  Lamberto Manzoli; Corrado De Vito; Carolina Marzuillo; Antonio Boccia; Paolo Villari
Journal:  Drug Saf       Date:  2012-03-01       Impact factor: 5.606

3.  Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial.

Authors:  Andrea Z LaCroix; Rowan T Chlebowski; JoAnn E Manson; Aaron K Aragaki; Karen C Johnson; Lisa Martin; Karen L Margolis; Marcia L Stefanick; Robert Brzyski; J David Curb; Barbara V Howard; Cora E Lewis; Jean Wactawski-Wende
Journal:  JAMA       Date:  2011-04-06       Impact factor: 56.272

4.  Hysterectomy, oophorectomy, and endogenous sex hormone levels in older women: the Rancho Bernardo Study.

Authors:  G A Laughlin; E Barrett-Connor; D Kritz-Silverstein; D von Mühlen
Journal:  J Clin Endocrinol Metab       Date:  2000-02       Impact factor: 5.958

5.  Hormone replacement therapy and associated risk of stroke in postmenopausal women.

Authors:  Rozenn N Lemaitre; Susan R Heckbert; Bruce M Psaty; Nicholas L Smith; Robert C Kaplan; W T Longstreth
Journal:  Arch Intern Med       Date:  2002-09-23

6.  Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial.

Authors:  Garnet L Anderson; Marian Limacher; Annlouise R Assaf; Tamsen Bassford; Shirley A A Beresford; Henry Black; Denise Bonds; Robert Brunner; Robert Brzyski; Bette Caan; Rowan Chlebowski; David Curb; Margery Gass; Jennifer Hays; Gerardo Heiss; Susan Hendrix; Barbara V Howard; Judith Hsia; Allan Hubbell; Rebecca Jackson; Karen C Johnson; Howard Judd; Jane Morley Kotchen; Lewis Kuller; Andrea Z LaCroix; Dorothy Lane; Robert D Langer; Norman Lasser; Cora E Lewis; JoAnn Manson; Karen Margolis; Judith Ockene; Mary Jo O'Sullivan; Lawrence Phillips; Ross L Prentice; Cheryl Ritenbaugh; John Robbins; Jacques E Rossouw; Gloria Sarto; Marcia L Stefanick; Linda Van Horn; Jean Wactawski-Wende; Robert Wallace; Sylvia Wassertheil-Smoller
Journal:  JAMA       Date:  2004-04-14       Impact factor: 56.272

7.  Estrogen plus progestin and risk of venous thrombosis.

Authors:  Mary Cushman; Lewis H Kuller; Ross Prentice; Rebecca J Rodabough; Bruce M Psaty; Randall S Stafford; Steven Sidney; Frits R Rosendaal
Journal:  JAMA       Date:  2004-10-06       Impact factor: 56.272

8.  Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis.

Authors:  Nicholas L Smith; Susan R Heckbert; Rozenn N Lemaitre; Alex P Reiner; Thomas Lumley; Noel S Weiss; Eric B Larson; Frits R Rosendaal; Bruce M Psaty
Journal:  JAMA       Date:  2004-10-06       Impact factor: 56.272

9.  Age at menopause, reproductive history, and venous thromboembolism risk among postmenopausal women: the Women's Health Initiative Hormone Therapy clinical trials.

Authors:  Marianne Canonico; Geneviève Plu-Bureau; Mary Jo O'Sullivan; Marcia L Stefanick; Barbara Cochrane; Pierre-Yves Scarabin; Joann E Manson
Journal:  Menopause       Date:  2014-03       Impact factor: 2.953

10.  Lower risk of cardiovascular events in postmenopausal women taking oral estradiol compared with oral conjugated equine estrogens.

Authors:  Nicholas L Smith; Marc Blondon; Kerri L Wiggins; Laura B Harrington; Astrid van Hylckama Vlieg; James S Floyd; Melody Hwang; Joshua C Bis; Barbara McKnight; Kenneth M Rice; Thomas Lumley; Frits R Rosendaal; Susan R Heckbert; Bruce M Psaty
Journal:  JAMA Intern Med       Date:  2014-01       Impact factor: 21.873

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.